Disulfide disruption reverses mucus dysfunction in allergic airway disease

Autor: Siddharth K. Shenoy, Corinne E. Hennessy, William J. Janssen, Fernando Holguin, Jung Soo Suk, Chelsea M. Magin, Christopher M. Evans, Ana M. Jaramillo, Vanessa L. Richardson, Naoko Hara, James C. NeeDell, Leslie E. Morgan, Diane E. Grove Villalon, Dorota S Raclawska, David J. Thornton, William R. Thelin, Nkechinyere A. Emezienna, Anna Q. Harder, Justin Hanes, Hassan M. El-Batal, Gregg A. Duncan
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
General Physics and Astronomy
urologic and male genital diseases
Biochemistry
Mice
0302 clinical medicine
fluids and secretions
immune system diseases
Bronchodilator
Medicine
030212 general & internal medicine
Disulfides
Respiratory system
Lung
Expectorants
0303 health sciences
Mice
Inbred BALB C

Multidisciplinary
Middle Aged
respiratory system
3. Good health
medicine.anatomical_structure
Female
medicine.symptom
medicine.drug
Adult
Adolescent
medicine.drug_class
Mucociliary clearance
Science
Inflammation
General Biochemistry
Genetics and Molecular Biology

Article
Allergic inflammation
03 medical and health sciences
In vivo
Hypersensitivity
Animals
Humans
030304 developmental biology
Asthma
Glycoproteins
business.industry
Mucin
General Chemistry
Translational research
medicine.disease
Mucus
respiratory tract diseases
Disease Models
Animal

030104 developmental biology
030228 respiratory system
Immunology
Methacholine
business
Zdroj: Nature Communications, Vol 12, Iss 1, Pp 1-9 (2021)
Nature Communications
ISSN: 2041-1723
Popis: Airway mucus is essential for lung defense, but excessive mucus in asthma obstructs airflow, leading to severe and potentially fatal outcomes. Current asthma treatments have minimal effects on mucus, and the lack of therapeutic options stems from a poor understanding of mucus function and dysfunction at a molecular level and in vivo. Biophysical properties of mucus are controlled by mucin glycoproteins that polymerize covalently via disulfide bonds. Once secreted, mucin glycopolymers can aggregate, form plugs, and block airflow. Here we show that reducing mucin disulfide bonds disrupts mucus in human asthmatics and reverses pathological effects of mucus hypersecretion in a mouse allergic asthma model. In mice, inhaled mucolytic treatment loosens mucus mesh, enhances mucociliary clearance, and abolishes airway hyperreactivity (AHR) to the bronchoprovocative agent methacholine. AHR reversal is directly related to reduced mucus plugging. These findings establish grounds for developing treatments to inhibit effects of mucus hypersecretion in asthma.
In asthma, mucus plugging is an important cause of airflow obstruction, but it is not targeted by widely used bronchodilator and anti-inflammatory drugs. Here the authors show that reduction of disulfide bonds that hold mucin polymers together reverses asthma-like obstruction in mice.
Databáze: OpenAIRE